

Amy Paller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/568374/publications.pdf>

Version: 2024-02-01

505
papers

32,134
citations

3933

88
h-index

6300

158
g-index

520
all docs

520
docs citations

520
times ranked

21934
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-reported outcomes for measuring sleep disturbance in pediatric atopic dermatitis: Cross-sectional study of the Patient Reported Outcomes Measurement Information System pediatric sleep measures and actigraphy. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 348-356.	1.2	9
2	Secukinumab responses vary across the spectrum of congenital ichthyosis in adults. <i>Archives of Dermatological Research</i> , 2023, 315, 305-315.	1.9	16
3	Single-question parent-reported global atopic dermatitis severity: A valid instrument in children. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 212-215.	1.2	2
4	Polygenic prediction of atopic dermatitis improves with atopic training and filaggrin factors. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 145-155.	2.9	11
5	Population pharmacokinetic and exposure-efficacy analysis of ixekizumab in paediatric patients with moderate-severe plaque psoriasis (IXORA-PEDS). <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1074-1086.	2.4	6
6	Prevalence of type 2 inflammatory diseases in pediatric patients with atopic dermatitis: Real-world evidence. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 758-765.	1.2	7
7	Generation and Validation of the Patient-Reported Outcome Measurement Information System Itch Questionnaire-Child (PIQ-C) to Measure the Impact of Itch on Life Quality. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1309-1317.e1.	0.7	6
8	IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis*. <i>British Journal of Dermatology</i> , 2022, 186, 496-507.	1.5	5
9	The Genomic and Phenotypic Landscape of Ichthyosis. <i>JAMA Dermatology</i> , 2022, 158, 16.	4.1	20
10	Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial data. <i>Pediatric Dermatology</i> , 2022, 39, 187-196.	0.9	23
11	Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12 years old with atopic dermatitis: Interim results from the PEDISTAD Real-World Registry. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1104-1108.	1.2	6
12	New therapies for atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 344-345.	1.0	8
13	American Academy of Dermatology Guidelines: Awareness of comorbidities associated with atopic dermatitis in adults. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1335-1336.e18.	1.2	54
14	Timing of itch among children with atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 603-605.	1.0	4
15	Development and Initial Validation of a Novel System to Assess Ichthyosis Severity. <i>JAMA Dermatology</i> , 2022, 158, 359.	4.1	4
16	Cytokine induced 3D organotypic psoriasis skin model demonstrates distinct roles for NF- κ B and JAK pathways in disease pathophysiology. <i>Experimental Dermatology</i> , 2022, 31, 1036-1047.	2.9	6
17	Self-Reported Health Outcomes of Children and Youth with 10 Chronic Diseases. <i>Journal of Pediatrics</i> , 2022, 246, 207-212.e1.	1.8	10
18	A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata. <i>Archives of Dermatological Research</i> , 2022, , .	1.9	15

#	ARTICLE	IF	CITATIONS
19	Optimizing topical management of atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 488-504.	1.0	10
20	Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a phase 2a proof-of-concept study. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1189-1191.	1.2	6
21	Burden and characteristics of skin pain among children with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1104-1106.e1.	3.8	3
22	Biologics for pediatric psoriasis: A systematic review and meta-analysis. <i>Pediatric Dermatology</i> , 2022, 39, 42-48.	0.9	11
23	Parent report of sleep health and attention regulation in a cross-sectional study of infants and preschool-aged children with atopic dermatitis. <i>Pediatric Dermatology</i> , 2022, 39, 61-68.	0.9	4
24	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD _v): a clinical outcome measure for the severity of atopic dermatitis. <i>British Journal of Dermatology</i> , 2022, 187, 531-538.	1.5	13
25	Transcriptomic Analysis of the Major Orphan Ichthyosis Subtypes Reveals Shared Immune and Barrier Signatures. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2363-2374.e18.	0.7	11
26	Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 533.	4.1	17
27	Cross-sectional characteristics of pediatric-onset discoid lupus erythematosus: Results of a multicenter, retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 559-566.	1.2	3
28	Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). <i>American Journal of Clinical Dermatology</i> , 2022, 23, 365-383.	6.7	30
29	Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1432-1449.	2.4	28
30	Bleach baths for atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 617-618.	1.0	4
31	Distinct skin microbiome community structures in congenital ichthyosis. <i>British Journal of Dermatology</i> , 2022, 187, 557-570.	1.5	11
32	Three-Question Skindex-Mini Measures Quality of Life in Children with Atopic Dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2022, , .	1.2	3
33	Tape strips capture atopic dermatitis-related changes in nonlesional skin throughout maturation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3445-3447.	5.7	11
34	Nocturnal movements in children with atopic dermatitis have a timing pattern: A case-control study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 474-476.	1.2	6
35	Early development of the skin microbiome: therapeutic opportunities. <i>Pediatric Research</i> , 2021, 90, 731-737.	2.3	14
36	Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 632-638.	1.2	77

#	ARTICLE	IF	CITATIONS
37	Characterization of CYP26B1-Selective Inhibitor, DX314, as a Potential Therapeutic for Keratinization Disorders. <i>Journal of Investigative Dermatology</i> , 2021, 141, 72-83.e6.	0.7	9
38	Rapid Capture and Extraction of Sweat for Regional Rate and Cytokine Composition Analysis Using a Wearable Soft Microfluidic System. <i>Journal of Investigative Dermatology</i> , 2021, 141, 433-437.e3.	0.7	17
39	Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 314-325.	5.7	61
40	SARS-CoV-2 receptor ACE2 protein expression in serum is significantly associated with age. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 875-878.	5.7	29
41	Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 432-470.	1.2	135
42	Characteristics and impacts of itch in children with inflammatory skin disorders*. <i>British Journal of Dermatology</i> , 2021, 184, 896-904.	1.5	9
43	Pediatric maculopapular cutaneous mastocytosis: Retrospective review of signs, symptoms, and associated conditions. <i>Pediatric Dermatology</i> , 2021, 38, 159-163.	0.9	8
44	Characterization of wound microbes in epidermolysis bullosa: Results from the epidermolysis bullosa clinical characterization and outcomes database. <i>Pediatric Dermatology</i> , 2021, 38, 119-124.	0.9	17
45	Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents. <i>Pediatric Dermatology</i> , 2021, 38, 164-180.	0.9	34
46	Incorporating joint pain screening into the pediatric dermatologic examination. <i>Pediatric Dermatology</i> , 2021, 38, 92-97.	0.9	3
47	New treatments in atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 21-31.	1.0	120
48	A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 464-475.	2.4	52
49	Vaccines do not cause atopic dermatitis: A systematic review and meta-analysis. <i>Vaccine</i> , 2021, 39, 1805-1811.	3.8	2
50	Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 243-255.	6.7	18
51	Preclinical assessment of dual CYP26[A1/B1] inhibitor, DX308, as an improved treatment for keratinization disorders. <i>Skin Health and Disease</i> , 2021, 1, e22.	1.5	2
52	Whole genome sequencing identifies novel genetic mutations in patients with eczema herpeticum. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2510-2523.	5.7	20
53	Acral Changes in pediatric patients during COVID 19 pandemic: Registry report from the COVID 19 response task force of the society of pediatric dermatology (SPD) and pediatric dermatology research alliance (PeDRA). <i>Pediatric Dermatology</i> , 2021, 38, 364-370.	0.9	14
54	A skin-conformable wireless sensor to objectively quantify symptoms of pruritus. <i>Science Advances</i> , 2021, 7, .	10.3	38

#	ARTICLE	IF	CITATIONS
55	Priority research questions in atopic dermatitis: an International Eczema Council eDelphi consensus. <i>British Journal of Dermatology</i> , 2021, 185, 203-205.	1.5	3
56	Supportive care in the acute phase of Stevensâ€“Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphiâ€“based consensus. <i>British Journal of Dermatology</i> , 2021, 185, 616-626.	1.5	22
57	Targeted Therapy for Pediatric Psoriasis. <i>Paediatric Drugs</i> , 2021, 23, 203-212.	3.1	11
58	Management of Severe Atopic Dermatitis in Pediatric Patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1462-1471.	3.8	16
59	Topical therapy of atopic dermatitis with a focus on pimecrolimus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1505-1518.	2.4	15
60	Reply to â€œCombined antibiotic, steroid, and moisturizer for atopic dermatitis: A 2â€“year case series of patientâ€“reported outcomesâ€“. <i>Pediatric Dermatology</i> , 2021, 38, 736-737.	0.9	1
61	Comprehensive pregnancy monitoring with a network of wireless, soft, and flexible sensors in high- and low-resource health settings. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	46
62	Epidermal SR-A Complexes Are Lipid Raft Based and Promote Nucleic Acid Nanoparticle Uptake. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1428-1437.e8.	0.7	6
63	Skin disease is more recalcitrant than muscle disease: A long-term prospective study of 184 children with juvenile dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1610-1618.	1.2	14
64	Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. <i>Lancet, The</i> , 2021, 397, 2151-2168.	13.7	259
65	Body site distribution of pediatric-onset morphea and association with extracutaneous manifestations. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 38-45.	1.2	7
66	The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 148-163.	2.9	72
67	Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderateâ€“toâ€“severe psoriasis: a <i>post hoc</i> analysis from IXORAâ€“PEDS. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e911-e913.	2.4	2
68	The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1318-1328.	4.7	6
69	JAK inhibitors in the treatment of atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 927-940.	2.9	129
70	<i>CARD14</i>â€“associated papulosquamous eruption (CAPE) in pediatric patients: Three additional cases and review of the literature. <i>Pediatric Dermatology</i> , 2021, 38, 1237-1242.	0.9	15
71	Sleep Disturbance in School-Aged Children with Atopic Dermatitis: Prevalence and Severity in a Cross-Sectional Sample. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3120-3129.e3.	3.8	23
72	Laboratory Safety of Dupilumab in Patients Aged 6â€“11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial. <i>Paediatric Drugs</i> , 2021, 23, 515-527.	3.1	15

#	ARTICLE	IF	CITATIONS
73	Multiethnic genome-wide and HLA association study of total serum IgE level. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1589-1595.	2.9	15
74	The atopic march and its prevention. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 289-290.	1.0	9
75	Cutaneous innervation in impaired diabetic wound healing. <i>Translational Research</i> , 2021, 236, 87-108.	5.0	47
76	Use of technology for the objective evaluation of scratching behavior: A systematic review. <i>JAAD International</i> , 2021, 5, 19-32.	2.2	8
77	Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 101-115.	6.7	32
78	Psoriasiform dermatitis during dupilumab treatment for moderate to severe atopic dermatitis in children. <i>Pediatric Dermatology</i> , 2021, 38, 1500-1505.	0.9	23
79	A retrospective analysis of diagnostic testing in a large North American cohort of patients with epidermolysis bullosa. <i>Journal of the American Academy of Dermatology</i> , 2021, .	1.2	3
80	Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older. <i>Dermatology and Therapy</i> , 2021, 11, 1643-1656.	3.0	1
81	Physician-reported Clinical Unmet Needs, Burden and Treatment Patterns of Paediatric Psoriasis Patients: A US and EU Real-world Evidence Study. <i>Acta Dermato-Venereologica</i> , 2021, 102, adv00660.	1.3	10
82	Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 389-397.	1.2	28
83	Treatment patterns of pediatric patients with atopic dermatitis: A claims data analysis. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 651-660.	1.2	22
84	Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 123-131.	1.2	71
85	Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 215-228.	2.9	70
86	Neurocognitive dysfunction and anaphylaxis in pediatric maculopapular cutaneous mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 409-410.	3.8	6
87	Targeting the IL-17 Receptor Using Liposomal Spherical Nucleic Acids as Topical Therapy for Psoriasis. <i>Journal of Investigative Dermatology</i> , 2020, 140, 435-444.e4.	0.7	36
88	Joint American Academy of Dermatology and National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 161-201.	1.2	129
89	Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis. <i>JAMA Dermatology</i> , 2020, 156, 44.	4.1	297
90	The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. <i>British Journal of Dermatology</i> , 2020, 182, 1331-1342.	1.5	102

#	ARTICLE	IF	CITATIONS
91	Update on pachyonychia congenita research. <i>British Journal of Dermatology</i> , 2020, 182, 788-789.	1.5	4
92	Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 119-131.	6.7	56
93	Association between the longitudinal course of AD, sleep disturbance, and overall health in US children. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 812-814.e1.	3.8	11
94	Diaper dermatitis prevalence and severity: Global perspective on the impact of caregiver behavior. <i>Pediatric Dermatology</i> , 2020, 37, 130-136.	0.9	34
95	Histopathologic findings characteristic of CARD14-associated papulosquamous eruption. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 425-430.	1.3	14
96	Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis. <i>Pediatric Dermatology</i> , 2020, 37, 1030-1037.	0.9	5
97	Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemic—Consensus: Recommendations by an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1222-1224.	1.2	7
98	Attenuation of Abnormal Scarring Using Spherical Nucleic Acids Targeting Transforming Growth Factor Beta 1. <i>ACS Applied Bio Materials</i> , 2020, 3, 8603-8610.	4.6	4
99	Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 ESSENCE Study. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 190.	2.7	9
100	Can a handheld device accurately measure barrier function in ichthyoses?. <i>Pediatric Dermatology</i> , 2020, 37, 860-863.	0.9	3
101	International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. <i>BMJ Open</i> , 2020, 10, e039928.	1.9	8
102	Gene Regulation Using Spherical Nucleic Acids to Treat Skin Disorders. <i>Pharmaceuticals</i> , 2020, 13, 360.	3.8	7
103	Loss-of-function variants in C3ORF52 result in localized autosomal recessive hypotrichosis. <i>Genetics in Medicine</i> , 2020, 22, 1227-1234.	2.4	12
104	Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodology. <i>BMJ Open</i> , 2020, 10, e033507.	1.9	6
105	Pathogenesis-Based Therapy With Repurposed Biologics for Monogenic Inflammatory Skin Disorders. <i>JAMA Dermatology</i> , 2020, 156, 839.	4.1	12
106	Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1282-1293.	1.2	214
107	Transepidermal water loss in the orphan forms of ichthyosis. <i>Pediatric Dermatology</i> , 2020, 37, 771-773.	0.9	3
108	Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (6 to 11 years old): The USTEKINUMAB for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (USTEKINUMAB-PSO) study. <i>British Journal of Dermatology</i> , 2020, 183, 664-672.	1.5	53

#	ARTICLE	IF	CITATIONS
109	Skin-interfaced biosensors for advanced wireless physiological monitoring in neonatal and pediatric intensive-care units. <i>Nature Medicine</i> , 2020, 26, 418-429.	30.7	272
110	Pigmented purpuric dermatosis in children: a retrospective cohort with emphasis on treatment and outcomes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2402-2408.	2.4	3
111	Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study). <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 158.	2.7	7
112	Topical calcineurin inhibitors for pediatric periorificial dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1409-1414.	1.2	12
113	Mutations in ASPRV1 Cause Dominantly Inherited Ichthyosis. <i>American Journal of Human Genetics</i> , 2020, 107, 158-163.	6.2	13
114	Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis. <i>JAMA Dermatology</i> , 2020, 156, 411.	4.1	241
115	Joint American Academy of Dermatologyâ€”National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1445-1486.	1.2	184
116	Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 579-590.	6.7	16
117	Product of Investigator Global Assessment and Body Surface Area (IGAxBSA): A practice-friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1187-1194.	1.2	20
118	Baricitinib in patients with moderateâ€”severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<sc>III</sc> trials. <i>British Journal of Dermatology</i> , 2020, 183, 242-255.	1.5	277
119	A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents. <i>JAMA Dermatology</i> , 2020, 156, 384.	4.1	33
120	Flotillin and AP2A1/2 Promote IGF-1 Receptor Association with Clathrin and Internalization in Primary Human Keratinocytes. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1743-1752.e4.	0.7	8
121	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 839-846.	1.2	78
122	No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 375-381.	1.2	64
123	Systemic immunosuppressive therapy for inflammatory skin diseases in children: Expert consensusâ€”based guidance for clinical decisionâ€”making during the COVIDâ€”19 pandemic. <i>Pediatric Dermatology</i> , 2020, 37, 424-434.	0.9	11
124	Efficacy and safety of ixekizumab in a phase <sc>III</sc> , randomized, doubleâ€”blind, placeboâ€”controlled study in paediatric patients with moderateâ€”severe plaque psoriasis () Tj ETQq0 0 0 rgBT 10 Overlock 70 Tf 50 1.	1.9	71
125	Effects of variations in access to care for children with atopic dermatitis. <i>BMC Dermatology</i> , 2020, 20, 24.	2.1	16
126	Biologics in Pediatric Psoriasis and Atopic Dermatitis: Revolutionizing the Treatment Landscape. , 2020, 106, 224-226;E1;E2.		0

#	ARTICLE	IF	CITATIONS
127	Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 604-618.	2.9	80
128	Which Nanobasics Should Be Taught in Medical Schools?. <i>AMA Journal of Ethics</i> , 2019, 21, E337-346.	0.7	3
129	Joint American Academy of Dermatology and National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 775-804.	1.2	105
130	Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 711-723.	6.7	21
131	Use of Tape Strips to Detect Immune and Barrier Abnormalities in the Skin of Children With Early-Onset Atopic Dermatitis. <i>JAMA Dermatology</i> , 2019, 155, 1358.	4.1	113
132	Replicated methylation changes associated with eczema herpeticum and allergic response. <i>Clinical Epigenetics</i> , 2019, 11, 122.	4.1	22
133	Profiling Immune Expression to Consider Repurposing Therapeutics for the Ichthyoses. <i>Journal of Investigative Dermatology</i> , 2019, 139, 535-540.	0.7	21
134	Use of dupilimab in pediatric atopic dermatitis: Access, dosing, and implications for managing severe atopic dermatitis. <i>Pediatric Dermatology</i> , 2019, 36, 172-176.	0.9	24
135	Defining and measuring "eczema control™": an international qualitative study to explore the views of those living with and treating atopic eczema. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1124-1132.	2.4	16
136	The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 510-519.	1.2	76
137	Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1224-1231.	2.4	50
138	Folic acid functionalized hollow nanoparticles for selective photodynamic therapy of cutaneous squamous cell carcinoma. <i>Materials Chemistry Frontiers</i> , 2019, 3, 1113-1122.	5.9	8
139	Sodium hypochlorite body wash in the management of <i>Staphylococcus aureus</i> colonized moderate-to-severe atopic dermatitis in infants, children, and adolescents. <i>Pediatric Dermatology</i> , 2019, 36, 442-447.	0.9	22
140	Systematic Review and Meta-analysis Comparing Topical Corticosteroids With Vehicle/Moisturizer in Childhood Atopic Dermatitis. <i>Journal of Pediatric Nursing</i> , 2019, 47, 36-43.	1.5	27
141	Binodal, wireless epidermal electronic systems with in-sensor analytics for neonatal intensive care. <i>Science</i> , 2019, 363, .	12.6	521
142	Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 807-815.	2.4	15
143	Second-Hit, Postzygotic <i>PMVK</i> and <i>MVD</i> Mutations in Linear Porokeratosis. <i>JAMA Dermatology</i> , 2019, 155, 548.	4.1	56
144	A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population. <i>Pediatric Dermatology</i> , 2019, 36, 290-297.	0.9	30

#	ARTICLE	IF	CITATIONS
145	Practice-based differences in paediatric discoid lupus erythematosus. <i>British Journal of Dermatology</i> , 2019, 181, 805-810.	1.5	8
146	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1029-1072.	1.2	542
147	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1073-1113.	1.2	281
148	Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America. <i>JAMA Dermatology</i> , 2019, 155, 196.	4.1	27
149	A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 89-98.e3.	1.2	118
150	Human and computational models of atopic dermatitis: A review and perspectives by an expert panel of the International Eczema Council. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 36-45.	2.9	58
151	The atopic march and atopic multimorbidity: Many trajectories, many pathways. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 46-55.	2.9	246
152	Epidermolysis Bullosa Simplex with KLHL24 Mutations Is Associated with Dilated Cardiomyopathy. <i>Journal of Investigative Dermatology</i> , 2019, 139, 244-249.	0.7	23
153	The microbiome in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 26-35.	2.9	317
154	Neurocognitive function in moderate-to-severe pediatric atopic dermatitis: A case-control study. <i>Pediatric Dermatology</i> , 2019, 36, 110-114.	0.9	12
155	Distinct transcriptomic profiles of early-onset atopic dermatitis in blood and skin of pediatric patients. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 122, 318-330.e3.	1.0	40
156	Introducing a curriculum in ethics and professionalism for dermatology residencies. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 1032-1034.	1.2	7
157	Developing drugs for treatment of atopic dermatitis in children (3 months to <18 years of age): Draft guidance for industry. <i>Pediatric Dermatology</i> , 2018, 35, 303-322.	0.9	16
158	Adverse events reported to the Food and Drug Administration from 2004 to 2016 for cosmetics and personal care products marketed to newborns and infants. <i>Pediatric Dermatology</i> , 2018, 35, 225-229.	0.9	10
159	Risk of intraocular and other extracutaneous involvement in patients with cutaneous juvenile xanthogranuloma. <i>Pediatric Dermatology</i> , 2018, 35, 329-335.	0.9	27
160	Topical Hypochlorite and Skin Acidification Improves Erythroderma of Omenn Syndrome. <i>Pediatrics</i> , 2018, 141, S408-S411.	2.1	2
161	Abnormal scar identification with spherical-nucleic-acid technology. <i>Nature Biomedical Engineering</i> , 2018, 2, 227-238.	22.5	67
162	Phosphodiesterase 4 inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, S43-S52.	1.2	81

#	ARTICLE	IF	CITATIONS
163	Pediatric psoriasis: Evolving perspectives. <i>Pediatric Dermatology</i> , 2018, 35, 170-181.	0.9	66
164	Biological Agents in <i>Pediatric Dermatology</i> , 2018, , 267-271.		0
165	The Major Orphan Forms of Ichthyosis Are Characterized by Systemic T-Cell Activation and Th-17/Tc-17/Th-22/Tc-22 Polarization in Blood. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2157-2167.	0.7	43
166	CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 487-494.	1.2	82
167	Sleep disturbance in children with moderate/severe atopic dermatitis: A case-control study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 336-341.	1.2	68
168	Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 579-590.e4.	1.2	48
169	The spectrum of manifestations in desmoplakin gene (DSP) spectrin repeat 6 domain mutations: Immunophenotyping and response to ustekinumab. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 498-505.e2.	1.2	58
170	Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. <i>British Journal of Dermatology</i> , 2018, 178, 768-775.	1.5	127
171	Clarification of methodology and further results from the pivotal phase 3 study of crisaborole for mild-moderate atopic dermatitis. <i>British Journal of Dermatology</i> , 2018, 178, 663-664.	1.5	1
172	Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 340-346.	2.0	9
173	Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families. <i>Dermatology and Therapy</i> , 2018, 8, 605-619.	3.0	18
174	Oligonucleotide Molecular Sprinkler for Intracellular Detection and Spontaneous Regulation of mRNA for Theranostics of Scar Fibroblasts. <i>Small</i> , 2018, 14, e1802546.	10.0	8
175	Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 821-838.	6.7	159
176	A march by any other name. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 137-138.	1.0	4
177	Response to "Comment on: "When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council" Journal of the American Academy of Dermatology, 2018, 79, e25-e26.	1.2	1
178	Gangliosides in Diabetic Wound Healing. <i>Progress in Molecular Biology and Translational Science</i> , 2018, 156, 229-239.	1.7	15
179	Early-onset pediatric atopic dermatitis is characterized by TH2/TH17/TH22-centered inflammation and lipid alterations. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 2094-2106.	2.9	176
180	Bacterial colonization, overgrowth, and superinfection in atopic dermatitis. <i>Clinics in Dermatology</i> , 2018, 36, 641-647.	1.6	25

#	ARTICLE	IF	CITATIONS
181	Targeted therapies for pediatric psoriasis. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018, 37, 167-172.	1.6	5
182	Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis. <i>Journal of Drugs in Dermatology</i> , 2018, 17, 187-194.	0.8	24
183	A clinical trial of intradermal and intramuscular seasonal influenza vaccination in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1575-1582.e8.	2.9	11
184	Optimizing Clinical Trials for Atopic Dermatitis in Children. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1363-1364.	0.7	4
185	Expanding the Genotypic Spectrum of Bathing Suit Ichthyosis. <i>JAMA Dermatology</i> , 2017, 153, 537.	4.1	17
186	Phenotypic spectrum of autosomal recessive congenital ichthyosis due to <i>PNPLA1</i> mutation. <i>British Journal of Dermatology</i> , 2017, 177, 319-322.	1.5	19
187	Topically Delivered Tumor Necrosis Factor-Targeted Gene Regulation for Psoriasis. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2027-2030.	0.7	22
188	Epidermolytic Ichthyosis Sine Epidermolysis. <i>American Journal of Dermatopathology</i> , 2017, 39, 440-444.	0.6	11
189	Cost-effectiveness of Prophylactic Moisturization for Atopic Dermatitis. <i>JAMA Pediatrics</i> , 2017, 171, e163909.	6.2	37
190	Pediatric Psoriasis Comorbidity Screening Guidelines. <i>JAMA Dermatology</i> , 2017, 153, 698.	4.1	84
191	Score of Toxic Epidermal Necrosis Predicts the Outcomes of Pediatric Epidermal Necrolysis. <i>Pediatric Dermatology</i> , 2017, 34, 433-437.	0.9	23
192	Mutations in <i>KDSR</i> Cause Recessive Progressive Symmetric Erythrokeratoderma. <i>American Journal of Human Genetics</i> , 2017, 100, 978-984.	6.2	67
193	Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 811-817.e4.	1.2	83
194	Alterations in B-cell subsets in pediatric patients with early atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 134-144.e9.	2.9	43
195	Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1519-1531.	3.8	141
196	Hermansky-Pudlak syndrome: Report of two patients with updated genetic classification and management recommendations. <i>Pediatric Dermatology</i> , 2017, 34, 638-646.	0.9	14
197	Potential impact of biologics and emerging therapies for psoriasis and atopic dermatitis on future fertility: Reassurance to patients but more data are needed. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 758-763.	1.2	10
198	Reply to: "Prognosis and management of Stevens-Johnson syndrome and toxic epidermal necrolysis". <i>Journal of the American Academy of Dermatology</i> , 2017, 77, e119.	1.2	0

#	ARTICLE	IF	CITATIONS
199	Safety of Systemic Agents for the Treatment of Pediatric Psoriasis. <i>JAMA Dermatology</i> , 2017, 153, 1147.	4.1	75
200	Therapeutic pipeline for atopic dermatitis: End of the drought?. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 633-643.	2.9	171
201	Oral Macrolides for the Dermatologic Manifestations of Blau Syndrome. <i>JAMA Dermatology</i> , 2017, 153, 1066.	4.1	2
202	Eczema, Atopic Dermatitis, or Atopic Eczema: Analysis of Global Search Engine Trends. <i>Dermatitis</i> , 2017, 28, 276-279.	1.6	5
203	Severity assessments used for inclusion criteria and baseline severity evaluation in atopic dermatitis clinical trials: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1890-1899.	2.4	11
204	When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 623-633.	1.2	170
205	Ganglioside GM3 Mediates Glucose-Induced Suppression of IGF-1 Receptor-Rac1 Activation to Inhibit Keratinocyte Motility. <i>Journal of Investigative Dermatology</i> , 2017, 137, 440-448.	0.7	22
206	Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 281-285.	1.2	73
207	Increasing Comorbidities Suggest that Atopic Dermatitis is a Systemic Disorder. <i>Journal of Investigative Dermatology</i> , 2017, 137, 18-25.	0.7	283
208	An IL-17 dominant immune profile is shared across the major orphan forms of ichthyosis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 152-165.	2.9	135
209	Juvenile Localized and Systemic Scleroderma. , 2017, , 75-89.		1
210	Study of the Atopic March: Development of Atopic Comorbidities. <i>Pediatric Dermatology</i> , 2016, 33, 388-398.	0.9	99
211	Epidermal necrosis with multinucleated keratinocytes: a possible diagnostic clue for dermatitis artefacta in children. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, e101-e102.	2.4	11
212	Association between atopic dermatitis and attention deficit hyperactivity disorder in U.S. children and adults. <i>British Journal of Dermatology</i> , 2016, 175, 920-929.	1.5	142
213	Ganglioside GM3 synthase depletion reverses neuropathic pain and small fiber neuropathy in diet-induced diabetic mice. <i>Molecular Pain</i> , 2016, 12, 174480691666628.	2.1	17
214	Temporal and Racial Differences Associated with Atopic Dermatitis Staphylococcus aureus and Encoded Virulence Factors. <i>MSphere</i> , 2016, 1, .	2.9	25
215	Accelerated T-cell activation and differentiation of polar subsets characterizes early atopic dermatitis development. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1473-1477.e5.	2.9	30
216	Physician-Industry Collaboration: Organizational Considerations for the Future of Innovation and Growth in Dermatology. <i>International Journal of Women's Dermatology</i> , 2016, 2, 60-61.	2.0	0

#	ARTICLE	IF	CITATIONS
217	Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. Journal of Allergy and Clinical Immunology, 2016, 138, 1639-1651.	2.9	309
218	Treatment of symptomatic epidermolysis bullosa simplex with botulinum toxin in a pediatric patient. JAAD Case Reports, 2016, 2, 259-260.	0.8	8
219	Oncofertility considerations in adolescents and young adults given a diagnosis of melanoma: Fertility risk of Food and Drug Administration-approved systemic therapies. Journal of the American Academy of Dermatology, 2016, 75, 528-534.	1.2	44
220	Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. Journal of the American Academy of Dermatology, 2016, 75, 494-503.e6.	1.2	425
221	Mycophenolate Mofetil and Mood Changes in Children with Skin Disorders. Pediatric Dermatology, 2016, 33, e216-7.	0.9	8
222	Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. Journal of the American Academy of Dermatology, 2016, 74, 280-287.e3.	1.2	84
223	Novel large animal model of xanthoma formation. Journal of Dermatological Science, 2016, 81, 203-205.	1.9	0
224	Mind the Gap: Sex Bias in Basic Skin Research. Journal of Investigative Dermatology, 2016, 136, 12-14.	0.7	27
225	Disorders of Hair and Nails. , 2016, , 136-174.e9.		2
226	Hereditary Disorders of Cornification. , 2016, , 95-118.e8.		3
227	Histiocytoses and Malignant Skin Diseases. , 2016, , 230-244.e3.		1
228	Cutaneous Disorders of the Newborn. , 2016, , 11-37.e4.		1
229	Disorders of Pigmentation. , 2016, , 245-278.e8.		0
230	Collagen Vascular Disorders. , 2016, , 509-539.e8.		0
231	Hereditary Disorders of the Dermis. , 2016, , 119-135.e6.		1
232	Bullous Disorders of Childhood. , 2016, , 317-333.e5.		4
233	Cutaneous Tumors and Tumor Syndromes. , 2016, , 193-229.e6.		0
234	Skin Signs of Other Systemic Diseases. , 2016, , 573-591.e6.		2

#	ARTICLE	IF	CITATIONS
235	Disorders of the Sebaceous and Sweat Glands. , 2016, , 175-192.e3.		0
236	The Hypersensitivity Syndromes. , 2016, , 467-494.e6.		2
237	Eczematous Eruptions in Childhood. , 2016, , 38-72.e7.		3
238	Viral Diseases of the Skin. , 2016, , 360-381.e3.		1
239	Vascular Disorders of Infancy and Childhood. , 2016, , 279-316.e6.		3
240	Photosensitivity and Photoreactions. , 2016, , 448-466.e4.		4
241	Papulosquamous and Related Disorders. , 2016, , 73-94.e4.		3
242	Interstitial lung disease in STING-associated vasculopathy with onset in infancy (SAVI): preliminary genotype-phenotype correlation. <i>Pediatric Rheumatology</i> , 2015, 13, .	2.1	3
243	Evaluation of Treatments for Pruritus in Epidermolysis Bullosa. <i>Pediatric Dermatology</i> , 2015, 32, 628-634.	0.9	28
244	Histologic and Immunohistochemical Features of the Skin Lesions in CANDLE Syndrome. <i>American Journal of Dermatopathology</i> , 2015, 37, 517-522.	0.6	39
245	Histological and Immunohistochemical Features of the Skin Lesions in CANDLE Syndrome. <i>Pediatric Rheumatology</i> , 2015, 13, .	2.1	0
246	Visualization of Sensory Neurons and Their Projections in an Upper Motor Neuron Reporter Line. <i>PLoS ONE</i> , 2015, 10, e0132815.	2.5	22
247	Association Between Eczema and Stature in 9 US Population-Based Studies. <i>JAMA Dermatology</i> , 2015, 151, 401.	4.1	47
248	Targeted deep sequencing identifies rare loss-of-function variants in IFNGR1 for risk of atopic dermatitis complicated by eczema herpeticum. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1591-1600.	2.9	42
249	Dominant De Novo Mutations in CJA1 Cause Erythrokeratoderma Variabilis et Progressiva, without Features of Oculodentodigital Dysplasia. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1540-1547.	0.7	48
250	The natural history of pediatric-onset discoid lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 628-633.	1.2	43
251	Prevalence and Characterization of Pruritus in Epidermolysis Bullosa. <i>Pediatric Dermatology</i> , 2015, 32, 53-59.	0.9	49
252	A systematic review of topical corticosteroid withdrawal (â€œsteroid addictionâ€) in patients with atopic dermatitis and other dermatoses. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 541-549.e2.	1.2	146

#	ARTICLE	IF	CITATIONS
253	Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. <i>Pediatric Allergy and Immunology</i> , 2015, 26, 306-315.	2.6	71
254	Central Obesity and High Blood Pressure in Pediatric Patients With Atopic Dermatitis. <i>JAMA Dermatology</i> , 2015, 151, 144.	4.1	86
255	siRNA-based spherical nucleic acids reverse impaired wound healing in diabetic mice by ganglioside GM3 synthase knockdown. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 5573-5578.	7.1	189
256	Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5-Year Randomized Trial. <i>Pediatrics</i> , 2015, 135, 597-606.	2.1	123
257	Sex-Based Biomedical Research Policy Needs an Implementation Plan. <i>Women's Health</i> , 2015, 11, 449-452.	1.5	3
258	Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)+ TH2/TH1 cell imbalance, whereas adults acquire CLA+ TH22/TC22 cell subsets. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 941-951.e3.	2.9	175
259	Translating Atopic Dermatitis Management Guidelines Into Practice for Primary Care Providers. <i>Pediatrics</i> , 2015, 136, 554-565.	2.1	78
260	Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 594-603.	1.2	187
261	Food Allergy in Infants With Atopic Dermatitis: Limitations of Food-Specific IgE Measurements. <i>Pediatrics</i> , 2015, 136, e1530-e1538.	2.1	55
262	Nocturnal eczema: Review of sleep and circadian rhythms in children with atopic dermatitis and future research directions. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1170-1177.	2.9	117
263	The Roles of Growth Factors in Keratinocyte Migration. <i>Advances in Wound Care</i> , 2015, 4, 213-224.	5.1	149
264	Sleep Disturbances in Adults with Eczema Are Associated with Impaired Overall Health: A US Population-Based Study. <i>Journal of Investigative Dermatology</i> , 2015, 135, 56-66.	0.7	258
265	Frequent somatic reversion of KRT1 mutations in ichthyosis with confetti. <i>Journal of Clinical Investigation</i> , 2015, 125, 1703-1707.	8.2	57
266	Laryngo-Onycho-Cutaneous Syndrome. , 2015, , 393-396.		1
267	Ganglioside GM3 Depletion Reverses Impaired Wound Healing in Diabetic Mice by Activating IGF-1 and Insulin Receptors. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1446-1455.	0.7	49
268	Pachyonychia Congenita in Pediatric Patients. <i>JAMA Dermatology</i> , 2014, 150, 146.	4.1	63
269	Ruth Kimmelstiel Freinkel (1926-2014). <i>Journal of Investigative Dermatology</i> , 2014, 134, 2669-2670.	0.7	3
270	Commentary: Learning to Support Sex Differences in Basic Science and Clinical Research. <i>Endocrinology</i> , 2014, 155, 1181-1183.	2.8	25

#	ARTICLE	IF	CITATIONS
271	Headaches as a Presenting Symptom of Linear Morphea en Coup de Sabre. <i>Pediatrics</i> , 2014, 134, e1715-e1719.	2.1	18
272	Multifunctional Skin-Like Electronics for Quantitative, Clinical Monitoring of Cutaneous Wound Healing. <i>Advanced Healthcare Materials</i> , 2014, 3, 1597-1607.	7.6	226
273	Excess Adiposity Preceding Pediatric Psoriasis. <i>JAMA Dermatology</i> , 2014, 150, 573.	4.1	46
274	Patient Satisfaction and Quality of Life in Psoriasis and Psoriatic Arthritis. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2676.	7.4	8
275	Guidelines of care for the management of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 327-349.	1.2	695
276	Guidelines of care for the management of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 116-132.	1.2	970
277	Methotrexate: New Uses for an Old Drug. <i>Journal of Pediatrics</i> , 2014, 164, 231-236.	1.8	61
278	The role of abnormalities in the distal pathway of cholesterol synthesis in the Congenital Hemidysplasia with Ichthyosiform erythroderma and Limb Defects (CHILD) syndrome. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2014, 1841, 345-352.	2.4	29
279	Guidelines of care for the management of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 338-351.	1.2	889
280	Filaggrin Gene Mutations in African Americans with Both Ichthyosis Vulgaris and Atopic Dermatitis. <i>Pediatric Dermatology</i> , 2014, 31, 489-492.	0.9	44
281	Guidelines of care for the management of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 1218-1233.	1.2	256
282	Activated STING in a Vascular and Pulmonary Syndrome. <i>New England Journal of Medicine</i> , 2014, 371, 507-518.	27.0	1,074
283	Eruptive Xanthomas Masquerading as Molluscum Contagiosum. <i>Pediatrics</i> , 2014, 134, e257-e260.	2.1	4
284	Current and Novel Approaches for Genetic Skin Disorders. , 2014, , 189-202.		0
285	Clinical Manifestations of Pediatric Psoriasis: Results of a Multicenter Study in the United States. <i>Pediatric Dermatology</i> , 2013, 30, 424-428.	0.9	92
286	Neurotoxicity in the setting of pediatric atopic dermatitis treated with modified cyclosporine and itraconazole. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, e177-e178.	1.2	4
287	Kawasaki disease. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 513.e1-513.e8.	1.2	77
288	Kawasaki disease. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 501.e1-501.e11.	1.2	47

#	ARTICLE	IF	CITATIONS
289	Whole-Exome Sequencing Reveals Somatic Mutations in HRAS and KRAS , which Cause Nevus Sebaceus. <i>Journal of Investigative Dermatology</i> , 2013, 133, 827-830.	0.7	79
290	Nano-Based Gene Therapy for Dermatologic Diseases. , 2013, , 109-117.		2
291	Pathogenesis-based therapies in ichthyoses. <i>Dermatologic Therapy</i> , 2013, 26, 46-54.	1.7	10
292	Congenital erosive and vesicular dermatosis with reticulated supple scarring: Unifying clinical features. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 909-915.	1.2	29
293	Association of Pediatric Psoriasis Severity With Excess and Central Adiposity. <i>JAMA Dermatology</i> , 2013, 149, 166.	4.1	148
294	Cutaneous dyspigmentation in patients with ganglioside GM3 synthase deficiency. <i>American Journal of Medical Genetics, Part A</i> , 2013, 161, 875-879.	1.2	43
295	Deacetylated GM3 Promotes uPAR-Associated Membrane Molecular Complex to Activate p38 MAPK in Metastatic Melanoma. <i>Molecular Cancer Research</i> , 2013, 11, 665-675.	3.4	13
296	Making a Mountain Out of a Molehill: NRAS, Mosaicism, and Large Congenital Nevi. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2127-2130.	0.7	24
297	The relationship between obesity and psoriasis in the pediatric population: implications and future directions. <i>Cutis</i> , 2013, 92, 107-9.	0.3	3
298	Out of the Skin of Babes: Measuring the Full Impact of Atopic Dermatitis in Infants and Young Children. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2494-2496.	0.7	3
299	Prescribing Patterns by Dermatologists and Primary Care Providers for Pediatric Psoriasis. <i>Archives of Dermatology</i> , 2012, 148, 71.	1.4	0
300	Effect of cat and daycare exposures on the risk of asthma in children with atopic dermatitis. <i>Allergy and Asthma Proceedings</i> , 2012, 33, 282-288.	2.2	26
301	Tretinoin Microsphere Gel 0.04% Pump for Treating Acne Vulgaris in Preadolescents: A Randomized, Controlled Study. <i>Pediatric Dermatology</i> , 2012, 29, 598-604.	0.9	10
302	Treatment Strategies for Atopic Dermatitis: Optimizing the Available Therapeutic Options. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2012, 31, S10-S17.	1.6	21
303	Latest Approaches to Treating Atopic Dermatitis. <i>Chemical Immunology and Allergy</i> , 2012, 96, 132-140.	1.7	9
304	Congenital hypertrichotic melanoneurocytoma: A congenital hypertrichotic plaque with overlapping neural and nevoid features. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 799-801.	1.2	1
305	Oral glycopyrrolate as second-line treatment for primary pediatric hyperhidrosis. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 918-923.	1.2	51
306	Atopic Dermatitis: Epidemiology and Pathogenesis Update. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2012, 31, S3-S5.	1.6	60

#	ARTICLE	IF	CITATIONS
307	Improving the Patient-Clinician and Parent-Clinician Partnership in Atopic Dermatitis Management. Seminars in Cutaneous Medicine and Surgery, 2012, 31, S23-S28.	1.6	10
308	Understanding and Managing Atopic Dermatitis in Adult Patients. Seminars in Cutaneous Medicine and Surgery, 2012, 31, S18-S22.	1.6	57
309	Current Issues in Atopic Comorbidities and Preventing the Atopic March. Seminars in Cutaneous Medicine and Surgery, 2012, 31, S6-S9.	1.6	19
310	Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 11975-11980.	7.1	361
311	Mutations in the Glycosylphosphatidylinositol Gene PIGL Cause CHIME Syndrome. American Journal of Human Genetics, 2012, 90, 685-688.	6.2	114
312	Vitamin D deficiency and rickets in children and adolescents with ichthyosiform erythroderma in type IV and V skin. British Journal of Dermatology, 2012, 166, 608-615.	1.5	24
313	Mutations in proteasome subunit β 2 type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis and Rheumatism, 2012, 64, 895-907.	6.7	340
314	Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. Journal of the American Academy of Dermatology, 2011, 64, 64-70.	1.2	65
315	Pathogenesis of the cutaneous phenotype in inherited disorders of cholesterol metabolism. Dermato-Endocrinology, 2011, 3, 100-106.	1.8	24
316	Dilute Bleach Baths for Staphylococcus aureus Colonization in Atopic Dermatitis to Decrease Disease Severity. Archives of Dermatology, 2011, 147, 246.	1.4	51
317	New Insights About Infant and Toddler Skin: Implications for Sun Protection. Pediatrics, 2011, 128, 92-102.	2.1	72
318	Pathogenesis-Based Therapy Reverses Cutaneous Abnormalities in an Inherited Disorder of Distal Cholesterol Metabolism. Journal of Investigative Dermatology, 2011, 131, 2242-2248.	0.7	95
319	The Yin and the Yang of Keratin Amino Acid Substitutions and Epidermolysis Bullosa Simplex. Journal of Investigative Dermatology, 2011, 131, 1787-1790.	0.7	14
320	Cutaneous Disorders of the Newborn. , 2011, , 10-36.		10
321	Hereditary Disorders of Cornification. , 2011, , 92-114.		4
322	Cutaneous Tumors and Tumor Syndromes. , 2011, , 184-218.		1
323	Histiocytoses and Malignant Skin Diseases. , 2011, , 219-233.		2
324	Vascular Disorders of Infancy and Childhood. , 2011, , 268-302.		7

#	ARTICLE	IF	CITATIONS
325	Viral Diseases of the Skin. , 2011, , 348-369.		3
326	The Hypersensitivity Syndromes. , 2011, , 454-482.		2
327	Collagen Vascular Disorders. , 2011, , 497-527.		5
328	Skin Signs of Other Systemic Diseases. , 2011, , 562-579.		2
329	Eczematous Eruptions in Childhood. , 2011, , 37-70.		2
330	Disorders of Pigmentation. , 2011, , 234-267.		2
331	Papulosquamous and Related Disorders. , 2011, , 71-91.		2
332	Disorders of Hair and Nails. , 2011, , 130-166.		2
333	Hereditary Disorders of the Dermis. , 2011, , 115-129.		0
334	Photosensitivity and Photoreactions. , 2011, , 436-453.		1
335	Efficacy and safety of etanercept in children and adolescents aged 8 years with severe plaque psoriasis. European Journal of Dermatology, 2010, 20, 323-328.	0.6	15
336	LUMBAR: Association between Cutaneous Infantile Hemangiomas of the Lower Body and Regional Congenital Anomalies. Journal of Pediatrics, 2010, 157, 795-801.e7.	1.8	153
337	Impediments to Research in Pediatric Dermatology: The Results of a Survey of the Members of the Society for Pediatric Dermatology. Pediatric Dermatology, 2010, 27, 337-340.	0.9	5
338	Insights from a Desmoplakin Mutation Identified in Lethal Acantholytic Epidermolysis Bullosa. Journal of Investigative Dermatology, 2010, 130, 2680-2683.	0.7	33
339	Adhesion and Migration, the Diverse Functions of the Laminin α 3 Subunit. Dermatologic Clinics, 2010, 28, 79-87.	1.7	39
340	Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome. Journal of the American Academy of Dermatology, 2010, 62, 489-495.	1.2	189
341	Intermittent etanercept therapy in pediatric patients with psoriasis. Journal of the American Academy of Dermatology, 2010, 63, 769-774.	1.2	42
342	Epidermal growth factor receptor inhibition with erlotinib for palmoplantar keratoderma. Journal of the American Academy of Dermatology, 2010, 63, e58-e59.	1.2	17

#	ARTICLE	IF	CITATIONS
343	Subgroup analyses of etanercept in pediatric patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, e38-e41.	1.2	8
344	Revised nomenclature and classification of inherited ichthyoses: Results of the First Ichthyosis Consensus Conference in Sorãze 2009. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 607-641.	1.2	610
345	Long-term etanercept in pediatric patients with plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 762-768.	1.2	96
346	Methylphenidate Transdermal System. Primary Care Companion To the <i>Journal of Clinical Psychiatry</i> , 2010, 12, .	0.6	3
347	Immunodeficiency Disorders. , 2010, , 575-588.		0
348	Unexpected Occurrence of Xeroderma Pigmentosum in an Uncle and Nephew. <i>Archives of Dermatology</i> , 2009, 145, 1285-91.	1.4	13
349	De- <i>N</i> -acetyl GM3 Promotes Melanoma Cell Migration and Invasion through Urokinase Plasminogen Activator Receptor Signalingâ€“Dependent MMP-2 Activation. <i>Cancer Research</i> , 2009, 69, 8662-8669.	0.9	31
350	The Misnomer â€œMacrocephalyâ€“Cutis Marmorata Telangiectatica Congenita Syndromeâ€“. <i>Archives of Dermatology</i> , 2009, 145, 287-93.	1.4	79
351	Loss-of-function mutations of an inhibitory upstream ORF in the human hairless transcript cause Marie Unna hereditary hypotrichosis. <i>Nature Genetics</i> , 2009, 41, 228-233.	21.4	190
352	Treatment of <i>Staphylococcus aureus</i> Colonization in Atopic Dermatitis Decreases Disease Severity. <i>Pediatrics</i> , 2009, 123, e808-e814.	2.1	441
353	Intertriginous pustular psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 679-683.	1.2	12
354	Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 260-269.e7.	2.9	227
355	GLI1 genotypes do not predict basal cell carcinoma risk: a case control study. <i>Molecular Cancer</i> , 2009, 8, 113.	19.2	3
356	Alteraciones de la cornificaci3n (ictiosis). , 2009, , 285-310.		0
357	Persistent association of nailfold capillaroscopy changes and skin involvement over thirtyâ€“six months with duration of untreated disease in patients with juvenile dermatomyositis. <i>Arthritis and Rheumatism</i> , 2008, 58, 571-576.	6.7	128
358	MAS063DP is Effective Monotherapy for Mild to Moderate Atopic Dermatitis in Infants and Children: A Multicenter, Randomized, Vehicle-Controlled Study. <i>Journal of Pediatrics</i> , 2008, 152, 854-859.	1.8	74
359	Etanercept Treatment for Children and Adolescents with Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2008, 358, 241-251.	27.0	366
360	From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 94-105.	1.2	109

#	ARTICLE	IF	CITATIONS
361	Pediatric morphea (localized scleroderma): Review of 136 patients. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 385-396.	1.2	232
362	Practical management of cutaneous reactions to the methylphenidate transdermal system: Recommendations from a dermatology expert panel consensus meeting. <i>Clinical Therapeutics</i> , 2008, 30, 326-337.	2.5	26
363	Three Times Weekly Tacrolimus Ointment Reduces Relapse in Stabilized Atopic Dermatitis: A New Paradigm for Use. <i>Pediatrics</i> , 2008, 122, e1210-e1218.	2.1	72
364	Disorders of Cornification (Ichthyosis). , 2008, , 285-310.		1
365	Suppression of Epidermal Growth Factor Receptor Signaling by Protein Kinase C- β Activation Requires CD82, Caveolin-1, and Ganglioside. <i>Cancer Research</i> , 2007, 67, 9986-9995.	0.9	96
366	Pityriasis lichenoides in childhood: A retrospective review of 124 patients. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 205-210.	1.2	124
367	Genetic Immunodeficiency Diseases. <i>Advances in Dermatology</i> , 2007, 23, 197-229.	2.0	5
368	Wnt signaling in focal dermal hypoplasia. <i>Nature Genetics</i> , 2007, 39, 820-821.	21.4	49
369	A systematic review of the safety of topical therapies for atopic dermatitis. <i>British Journal of Dermatology</i> , 2007, 156, 203-221.	1.5	171
370	Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial. <i>British Journal of Dermatology</i> , 2007, 157, 378-381.	1.5	18
371	Tacrolimus Ointment is Effective for Psoriasis on the Face and Intertriginous Areas in Pediatric Patients. <i>Pediatric Dermatology</i> , 2007, 24, 76-80.	0.9	86
372	Patient perspectives on the management of atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 226-232.	2.9	274
373	The epidemiology of molluscum contagiosum in children. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 47-54.	1.2	153
374	Ectodermal dysplasia—skin fragility syndrome resulting from a new homozygous mutation, 888delC, in the desmosomal protein plakophilin 1. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 157-161.	1.2	40
375	Incontinentia pigmenti in male patients. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 251-255.	1.2	59
376	The acanthosis nigricans form of epidermal nevus. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 696-698.	1.2	33
377	The relationship between family medical history and childhood vitiligo. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 238-244.	1.2	56
378	"Free-Floating" Desmosomes in Lipoid Proteinosis: An Inherent Defect in Keratinocyte Adhesion?. <i>Pediatric Dermatology</i> , 2006, 23, 1-6.	0.9	24

#	ARTICLE	IF	CITATIONS
379	Lipid Rafts: Membrane Triage Centers. <i>Journal of Investigative Dermatology</i> , 2006, 126, 951-953.	0.7	19
380	Ganglioside GM3 Promotes Carcinoma Cell Proliferation via Urokinase Plasminogen Activator-Induced Extracellular Signal-Regulated Kinase-Independent p70S6 Kinase Signaling. <i>Journal of Investigative Dermatology</i> , 2006, 126, 2687-2696.	0.7	26
381	Gangliosides Inhibit Urokinase-Type Plasminogen Activator (uPA)-Dependent Squamous Carcinoma Cell Migration by Preventing uPA Receptor/ β 5 α 1 Integrin/Epidermal Growth Factor Receptor Interactions. <i>Journal of Investigative Dermatology</i> , 2005, 124, 839-848.	0.7	40
382	Asymptomatic Inflammatory Bowel Disease Presenting With Mucocutaneous Findings. <i>Pediatrics</i> , 2005, 116, e439-e444.	2.1	61
383	Consensus Statement on the Safety Profile of Topical Calcineurin Inhibitors. <i>Dermatology</i> , 2005, 211, 77-78.	2.1	54
384	The Economics of Topical Immunomodulators for the Treatment of Atopic Dermatitis. <i>Pharmacoeconomics</i> , 2005, 23, 543-566.	3.3	10
385	Jorizzo JL, Crouse RG, Wheeler CE, Jr. Lamellar ichthyosis, dwarfism, mental retardation, and hair shaft abnormalities. <i>J Am Acad Dermatol</i> 1980;2:309-17.. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 630.	1.2	0
386	Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: Results from 3 randomized, comparative studies. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 810-822.	1.2	138
387	Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, S186-S194.	1.2	125
388	Genetic immunodeficiency disorders. <i>Clinics in Dermatology</i> , 2005, 23, 68-77.	1.6	4
389	Acute Generalized Exanthematous Pustulosis in Children. <i>Archives of Dermatology</i> , 2004, 140, 1172-3.	1.4	40
390	New KIT mutations in patients with piebaldism. <i>Journal of Dermatological Science</i> , 2004, 35, 29-33.	1.9	41
391	Tacrolimus ointment promotes repigmentation of vitiligo in children: A review of 57 cases. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 760-766.	1.2	134
392	Leukotriene receptor antagonists are ineffective for severe atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, 485-486.	1.2	20
393	Infantile systemic hyalinosis. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, 61-64.	1.2	46
394	Piecing together the puzzle of cutaneous mosaicism. <i>Journal of Clinical Investigation</i> , 2004, 114, 1407-1409.	8.2	23
395	Piecing together the puzzle of cutaneous mosaicism. <i>Journal of Clinical Investigation</i> , 2004, 114, 1407-1409.	8.2	10
396	Extracellular Matrix Protein 1 Gene (ECM1) Mutations in Lipoid Proteinosis and Genotype-Phenotype Correlation. <i>Journal of Investigative Dermatology</i> , 2003, 120, 345-350.	0.7	119

#	ARTICLE	IF	CITATIONS
397	Compound Heterozygous Mutations in the Hairless Gene in Atrichia with Papular Lesions. <i>Journal of Investigative Dermatology</i> , 2003, 121, 430-432.	0.7	20
398	Topically Applied Imiquimod Inhibits Vascular Tumor Growth In Vivo. <i>Journal of Investigative Dermatology</i> , 2003, 121, 1205-1209.	0.7	97
399	In This Issue: Genotype-Phenotype Correlations: Lessons Learned from "Milder" Genodermatoses. <i>Journal of Investigative Dermatology</i> , 2003, 120, vi-vii.	0.7	0
400	Livedo Reticularis in a Child with Moyamoya Disease. <i>Pediatric Dermatology</i> , 2003, 20, 124-127.	0.9	18
401	Erythema Dyschromicum Persists in Prepubertal Children. <i>Pediatric Dermatology</i> , 2003, 20, 398-403.	0.9	43
402	Raised limb bands developing in infancy. <i>British Journal of Dermatology</i> , 2003, 149, 436-437.	1.5	16
403	Atopic dermatitis and the atopic march. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, S118-S127.	2.9	946
404	AAD consensus statement on psoriasis therapies. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 897-899.	1.2	110
405	Fluocinolone acetonide 0.01% in peanut oil: Therapy for childhood atopic dermatitis, even in patients who are peanut sensitive. <i>Journal of the American Academy of Dermatology</i> , 2003, 48, 569-577.	1.2	35
406	Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2003, 48, 553-563.	1.2	62
407	Mutations in Capillary Morphogenesis Gene-2 Result in the Allelic Disorders Juvenile Hyaline Fibromatosis and Infantile Systemic Hyalinosis. <i>American Journal of Human Genetics</i> , 2003, 73, 957-966.	6.2	174
408	Ganglioside GM3 Inhibits Matrix Metalloproteinase-9 Activation and Disrupts Its Association with Integrin. <i>Journal of Biological Chemistry</i> , 2003, 278, 25591-25599.	3.4	40
409	Infants With "Hair Today That's Gone Tomorrow". <i>Archives of Dermatology</i> , 2003, 139, 1644-5.	1.4	3
410	Ganglioside GM3 Blocks the Activation of Epidermal Growth Factor Receptor Induced by Integrin at Specific Tyrosine Sites. <i>Journal of Biological Chemistry</i> , 2003, 278, 48770-48778.	3.4	77
411	Safe treatment of head/neck AD with Tacrolimus ointment. <i>Journal of Dermatological Treatment</i> , 2003, 14, 86-94.	2.2	22
412	Genetic Disorders of Skin. <i>Archives of Dermatology</i> , 2003, 139, 74.	1.4	5
413	Ganglioside Modulation Regulates Epithelial Cell Adhesion and Spreading via Ganglioside-specific Effects on Signaling. <i>Journal of Biological Chemistry</i> , 2002, 277, 40410-40419.	3.4	31
414	Ganglioside Induces Caveolin-1 Redistribution and Interaction with the Epidermal Growth Factor Receptor. <i>Journal of Biological Chemistry</i> , 2002, 277, 47028-47034.	3.4	70

#	ARTICLE	IF	CITATIONS
415	Perceptions of Physicians and Pediatric Patients About Atopic Dermatitis, Its Impact, and Its Treatment. <i>Clinical Pediatrics</i> , 2002, 41, 323-332.	0.8	88
416	Incontinentia pigmenti: A review and update on the molecular basis of pathophysiology. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, 169-190.	1.2	269
417	Inherited disorders of keratinization. <i>Current Problems in Dermatology</i> , 2002, 14, 77-115.	0.0	1
418	Two Cases of Primarily Palmoplantar Keratoderma Associated with Novel Mutations in Keratin 1. <i>Journal of Investigative Dermatology</i> , 2002, 119, 966-971.	0.7	49
419	Ganglioside Loss Promotes Survival Primarily by Activating Integrin-Linked Kinase/Akt Without Phosphoinositide 3-OH Kinase Signaling. <i>Journal of Investigative Dermatology</i> , 2002, 119, 107-117.	0.7	30
420	Pustular Miliaria Rubra: A Specific Cutaneous Finding of Type I Pseudohypoaldosteronism. <i>Pediatric Dermatology</i> , 2002, 19, 317-319.	0.9	45
421	Expression of eotaxin, an eosinophil-selective chemokine, parallels eosinophil accumulation in the vesiculobullous stage of incontinentia pigmenti. <i>Clinical and Experimental Immunology</i> , 2002, 127, 470-478.	2.6	49
422	Inherited disorders of keratinization. <i>Current Problems in Dermatology</i> , 2002, 014, 71-116.	0.0	3
423	A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, S47-S57.	1.2	278
424	A novel KIT mutation results in piebaldism with progressive depigmentation. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 288-292.	1.2	89
425	Aquagenic palmoplantar keratoderma. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 696-699.	1.2	111
426	Ongoing blistering in a boy with congenital erosive and vesicular dermatosis healing with reticulated supple scarring. <i>Journal of the American Academy of Dermatology</i> , 2001, 45, 946-948.	1.2	31
427	Use of nonsteroidal topical immunomodulators for the treatment of atopic dermatitis in the pediatric population. <i>Journal of Pediatrics</i> , 2001, 138, 163-168.	1.8	23
428	Inhibition of Integrin-linked Kinase/Protein Kinase B/Akt Signaling. <i>Journal of Biological Chemistry</i> , 2001, 276, 44504-44511.	3.4	61
429	Ganglioside Modulates Ligand Binding to the Epidermal Growth Factor Receptor. <i>Journal of Investigative Dermatology</i> , 2001, 116, 69-76.	0.7	46
430	Carbohydrate-Carbohydrate Binding of Ganglioside to Integrin $\alpha 5$ Modulates $\alpha 5 \beta 1$ Function. <i>Journal of Biological Chemistry</i> , 2001, 276, 8436-8444.	3.4	70
431	Langerhans Cell Histiocytosis Presenting in the Neonatal Period. <i>JAMA Pediatrics</i> , 2001, 155, 778.	3.0	136
432	Expanding Our Concepts of Mosaic Disorders of Skin. <i>Archives of Dermatology</i> , 2001, 137, 1236-8.	1.4	22

#	ARTICLE	IF	CITATIONS
433	Epidermal growth factor receptor glycosylation is required for ganglioside GM3 binding and GM3-mediated suppression of activation. <i>Glycobiology</i> , 2001, 11, 515-522.	2.5	77
434	What Syndrome Is This?. <i>Pediatric Dermatology</i> , 2001, 18, 252-254.	0.9	9
435	Responses to Anti-Angiogenic Therapies. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2000, 5, 83-86.	0.8	13
436	Squaric acid immunotherapy for warts in children. <i>Journal of the American Academy of Dermatology</i> , 2000, 42, 803-808.	1.2	70
437	Collagen vascular diseases in children. <i>Current Problems in Dermatology</i> , 2000, 12, 177-182.	0.0	0
438	DERMATOLOGIC CLUES TO INHERITED DISEASE. <i>Pediatric Clinics of North America</i> , 2000, 47, 825-839.	1.8	4
439	Bullous Systemic Lupus Erythematosus With Autoantibodies Recognizing Multiple Skin Basement Membrane Components, Bullous Pemphigoid Antigen 1, Laminin-5, Laminin-6, and Type VII Collagen. <i>Archives of Dermatology</i> , 1999, 135, 569-73.	1.4	108
440	Ultrapotent Topical Corticosteroid Treatment of Childhood Genital Lichen Sclerosus. <i>Archives of Dermatology</i> , 1999, 135, 525-8.	1.4	75
441	Hedgehog Hives. <i>Archives of Dermatology</i> , 1999, 135, 561-3.	1.4	35
442	In Vivo Gene Therapy with Interleukin-12 Inhibits Primary Vascular Tumor Growth and Induces Apoptosis in a Mouse Model. <i>Journal of Investigative Dermatology</i> , 1999, 112, 775-781.	0.7	35
443	The Molecular Bases for the Palmoplantar Keratodermas. <i>Pediatric Dermatology</i> , 1999, 16, 483-486.	0.9	10
444	Infantile acropustulosis revisited: history of scabies and response to topical corticosteroids. <i>Pediatric Dermatology</i> , 1998, 15, 337-341.	0.9	58
445	Topical calcipotriene for morphea/linear scleroderma. <i>Journal of the American Academy of Dermatology</i> , 1998, 39, 211-215.	1.2	182
446	Mucocutaneous manifestations of the hyper-IgM immunodeficiency syndrome. <i>Journal of the American Academy of Dermatology</i> , 1998, 38, 191-196.	1.2	33
447	Partial albinism with immunodeficiency: Criscelli syndrome: Report of a case and review of the literature. <i>Journal of the American Academy of Dermatology</i> , 1998, 38, 295-300.	1.2	116
448	Effects of a low-potency corticosteroid lotion plus a moisturizing regimen in the treatment of atopic dermatitis. <i>Current Therapeutic Research</i> , 1998, 59, 227-233.	1.2	47
449	Integrin $\alpha 5 \beta 1$ Expression Is Required for Inhibition of Keratinocyte Migration by Ganglioside GT1b. <i>Experimental Cell Research</i> , 1998, 239, 311-319.	2.6	27
450	Inefficacy of oral cimetidine for nonatopic children with molluscum contagiosum [letter; comment]. <i>Pediatric Dermatology</i> , 1998, 15, 71-72.	0.9	19

#	ARTICLE	IF	CITATIONS
451	Mosaicism and Epidermal Nevi. , 1998, , 713-717.		0
452	Consequences of Seven Novel Mutations on the Expression and Structure of Keratinocyte Transglutaminase. Journal of Biological Chemistry, 1997, 272, 21018-21026.	3.4	63
453	Guidelines of care for neurofibromatosis type 1. Journal of the American Academy of Dermatology, 1997, 37, 625-630.	1.2	31
454	Pulmonary Hemorrhage: An Often Fatal Complication of Henoch-Schoenlein Purpura. Pediatric Dermatology, 1997, 14, 299-302.	0.9	38
455	What Syndrome Is This?. Pediatric Dermatology, 1997, 14, 403-405.	0.9	22
456	What Syndrome Is This?. Pediatric Dermatology, 1996, 13, 63-64.	0.9	7
457	The Use of Pulse Corticosteroid Therapy for Juvenile Dermatomyositis. Pediatric Dermatology, 1996, 13, 347-348.	0.9	16
458	Prenatal Diagnosis for Recessive Dystrophic Epidermolysis Bullosa in 10 Families by Mutation and Haplotype Analysis in the Type VII Collagen Gene (COL7A1). Molecular Medicine, 1996, 2, 59-76.	4.4	55
459	Pigmentary Patterning as a Clinical Clue of Genetic Mosaicism. Archives of Dermatology, 1996, 132, 1234.	1.4	10
460	Stump the Experts. Dermatologic Surgery, 1995, 21, 361-362.	0.8	2
461	Stump the Experts. Dermatologic Surgery, 1995, 21, 284.	0.8	2
462	Ganglioside GT1b Inhibits Keratinocyte Adhesion and Migration on a Fibronectin Matrix. Journal of Investigative Dermatology, 1995, 105, 237-242.	0.7	29
463	Response of deep tufted angioma to interferon alfa. Journal of the American Academy of Dermatology, 1995, 33, 124-126.	1.2	76
464	Clinical Pearl: Use of self-adhesive, compressive wraps in the treatment of limb hemangiomas. Journal of the American Academy of Dermatology, 1995, 32, 117-118.	1.2	30
465	Ataxia-telangiectasia. Journal of the American Academy of Dermatology, 1995, 32, 686.	1.2	0
466	Multiple Cutaneous Nodules in a Newborn. Pediatric Dermatology, 1995, 12, 59-62.	0.9	0
467	Ganglioside GT1b Induces Keratinocyte Differentiation without Activating Protein Kinase C. Experimental Cell Research, 1995, 217, 118-124.	2.6	19
468	Update on selected inherited immunodeficiency syndromes. Seminars in Dermatology, 1995, 14, 60-65.	0.6	3

#	ARTICLE	IF	CITATIONS
469	Laboratory Tests for Ichthyosis. <i>Dermatologic Clinics</i> , 1994, 12, 99-107.	1.7	23
470	Genetic and Clinical Mosaicism in a Type of Epidermal Nevus. <i>New England Journal of Medicine</i> , 1994, 331, 1408-1415.	27.0	307
471	Cracks in the foundation: keratin filaments and genetic disease. <i>Trends in Cell Biology</i> , 1994, 4, 321-326.	7.9	25
472	Leukocyte adhesion deficiency: Recurrent childhood skin infections. <i>Journal of the American Academy of Dermatology</i> , 1994, 31, 316-319.	1.2	16
473	Ganglioside GM3 Inhibits the Proliferation of Cultured Keratinocytes. <i>Journal of Investigative Dermatology</i> , 1993, 100, 841-845.	0.7	48
474	Atrophie blanche with onset in childhood. <i>Journal of Pediatrics</i> , 1993, 123, 753-755.	1.8	9
475	Association of facial hemangiomas with Dandy-Walker and other posterior fossa malformations. <i>Journal of Pediatrics</i> , 1993, 122, 379-384.	1.8	125
476	Cimetidine therapy for multiple viral warts in children. <i>Journal of the American Academy of Dermatology</i> , 1993, 28, 794-796.	1.2	92
477	Eosinophilic Pustular Folliculitis in Infancy and Childhood. <i>JAMA Pediatrics</i> , 1993, 147, 197.	3.0	11
478	Pseudoporphyria cutanea tarda: Two case reports on children receiving peritoneal dialysis and erythropoietin therapy. <i>Journal of Pediatrics</i> , 1992, 121, 749-752.	1.8	25
479	Treatment of cutaneous hemangiomas by the flashlamp-pumped pulsed dye laser: Prospective analysis. <i>Journal of Pediatrics</i> , 1992, 120, 555-560.	1.8	199
480	The genetic basis of epidermolytic hyperkeratosis: A disorder of differentiation-specific epidermal keratin genes. <i>Cell</i> , 1992, 70, 811-819.	28.9	335
481	Chediak-Higashi Syndrome in a Black Child. <i>Pediatric Dermatology</i> , 1992, 9, 31-36.	0.9	14
482	Cutaneous <i>Fusarium</i> Infection in an Adolescent with Acute Leukemia. <i>Pediatric Dermatology</i> , 1992, 9, 62-65.	0.9	15
483	Alteration in Keratinocyte Ganglioside Content in Basal Cell Carcinomas. <i>Journal of Investigative Dermatology</i> , 1992, 98, 226-232.	0.7	35
484	Cutaneous granulomatous lesions in patients with ataxia-telangiectasia. <i>Journal of Pediatrics</i> , 1991, 119, 917-922.	1.8	72
485	Graft-versus-host disease following ECMO. <i>Journal of Pediatric Surgery</i> , 1991, 26, 317-319.	1.6	23
486	Point mutations in human keratin 14 genes of epidermolysis bullosa simplex patients: Genetic and functional analyses. <i>Cell</i> , 1991, 66, 1301-1311.	28.9	657

#	ARTICLE	IF	CITATIONS
487	Nasal Midline Masses in Infants and Children. Archives of Dermatology, 1991, 127, 362.	1.4	73
488	Pachyonychia Congenita Tarda. Archives of Dermatology, 1991, 127, 701.	1.4	35
489	Pyoderma gangrenosum in pediatric acquired immunodeficiency syndrome. Journal of Pediatrics, 1990, 117, 63-66.	1.8	52
490	The Discrimination Between CD8+ Cytotoxic and CD8+ Suppressor Lymphocyte Subsets Within Cutaneous Infiltrates-Reply. Archives of Dermatology, 1989, 125, 845.	1.4	0
491	Fibrous Hamartoma of Infancy. Archives of Dermatology, 1989, 125, 88.	1.4	48
492	Absence of a Stratum Corneum Antigen in Disorders of Epidermal Cell Proliferation: Detection with an Anti-Ganglioside GM3 Antibody. Journal of Investigative Dermatology, 1989, 92, 240-246.	0.7	15
493	Disseminated Fusarium solani Infection With Cutaneous Nodules in a Bone Marrow Transplant Patient. International Journal of Dermatology, 1988, 27, 698-701.	1.0	37
494	T-Lymphocyte Subsets in the Lesional Skin of Allogeneic and Autologous Bone Marrow Transplant Patients. Archives of Dermatology, 1988, 124, 1795.	1.4	28
495	Localization of the Alpha 3 (V) Chain of Type V Collagen in Human Skin. Journal of Investigative Dermatology, 1987, 88, 246-252.	0.7	19
496	Organ-Specific, Phylogenetic, and Ontogenetic Distribution of the Epidermolysis Bullosa Acquisita Antigen. Journal of Investigative Dermatology, 1986, 86, 376-379.	0.7	44
497	Knuckle Pads in Children. JAMA Pediatrics, 1986, 140, 915.	3.0	14
498	The Generalized Atrophic Benign Form of Junctional Epidermolysis Bullosa. Archives of Dermatology, 1986, 122, 704.	1.4	35
499	Dermatologic Uses of Methotrexate in Children: Indications and Guidelines. Pediatric Dermatology, 1985, 2, 238-243.	0.9	13
500	A Mouse Monoclonal Antibody Against a Newly Discovered Basement Membrane Component, the Epidermolysis Bullosa Acquisita Antigen. Journal of Investigative Dermatology, 1985, 84, 215-217.	0.7	52
501	Extensive Ichthyosiform Sarcoidosis in a Patient With Juvenile Rheumatoid Arthritis. Archives of Dermatology, 1985, 121, 171.	1.4	4
502	Primary Cutaneous T-cell Lymphoma in a Child. Pediatric Dermatology, 1984, 2, 131-135.	0.9	23
503	Pedal hemangiomas in Turner syndrome. Journal of Pediatrics, 1983, 103, 87-88.	1.8	12
504	Cutaneous Sarcoidosis Associated With Sarcoidosis of the Upper Airway. Archives of Dermatology, 1983, 119, 592.	1.4	11

#	ARTICLE	IF	CITATIONS
505	Efficacy and Safety of Topical Nitric Oxide-releasing Berdazimer Gel in Patients With Molluscum Contagiosum. JAMA Dermatology, 0, , .	4.1	7